EU regulator recommends revoking approval for Novartis’ sickle cell disease drug
The EMA’s human medicines committee concluded that the benefits of Adakveo did not outweigh its risks
Read More
Tag: Adakveo
NICE turns down Novartis’ Adakveo
Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said
Read More
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
- TARA-002 shows strong early results in trial for paediatric lymphatic malformations
- Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
- Cellbyte raises $2.75m to slash drug launch timelines with AI
- GSK and Imperial launch £45m AI-powered AMR research drive
- Scottish Brain Sciences opens new Alzheimer’s research centre in Aberdeen
